Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis

Sadeleştirilmiş öğe sayfası
dc.contributor.authorYapali, Suna
dc.contributor.authorGokcan, Hale
dc.contributor.authorDurak, Serdar
dc.contributor.authorEllik, Zeynep Melekoglu
dc.contributor.authorGuzelbulut, Fatih
dc.contributor.authorVatansever, Sezgin
dc.contributor.authorAri, Derya
dc.contributor.authorMehdiyev, Shahin
dc.contributor.authorAdanir, Haydar
dc.contributor.authorKoc, Elif Sitre
dc.contributor.authorGunduz, Feyza
dc.contributor.authorArslan, Mehmet
dc.contributor.authorOzdil, Kamil
dc.contributor.authorDincer, Dinc
dc.contributor.authorIdilman, Ramazan
dc.date.accessioned2025-10-16T15:17:10Z
dc.date.issued2022
dc.description.abstractInternational Liver Congress, London, ENGLAND, JUN 22-26, 2022
dc.identifier.otherWOS:000826275104265
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6875
dc.publisherELSEVIER
dc.sourceJOURNAL OF HEPATOLOGY
dc.titleReal life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS